Osiris Therapeutics

Osiris Therapeutics, Inc. was founded in 1992 based on stem cell technology discovered by researchers at Case Western Reserve University led by Dr. Arnold Caplan. He recognized this technology had tremendous therapeutic potential.
Today, more than two decades after the journey began, Osiris continues to advance the science of cellular regenerative medicine to treat patients in need. Osiris Therapeutics, based in Columbia, Maryland, is the world leader in researching, developing and marketing regenerative medicine products. Having developed the world’s first approved stem cell drug, the company continues to advance its research and development in biotechnology by focusing on innovation in regenerative medicine – including bioengineering, stem cell research and viable tissue based products. Osiris has achieved commercial success with products in orthopaedics, sports medicine and wound care, including BIO4™, Cartiform® and Grafix®. Osiris, Grafix, and Cartiform are registered trademarks of Osiris Therapeutics, Inc. BIO4 is a trademark of Stryker Corporation (NYSE: SYK).

Type
Public
HQ
Columbia, US
Employees
211 (est)
Osiris Therapeutics is headquartered in Columbia, US

Key People at Osiris Therapeutics

Lode Debrabandere

Lode Debrabandere

Prsident & CEO
Philip R. Jacoby

Philip R. Jacoby

CFO
Michelle LeRoux Williams

Michelle LeRoux Williams

CSO

Osiris Therapeutics Locations

Columbia, US

Osiris Therapeutics Metrics

Osiris Therapeutics Summary

Market capitalization

$179 M

Closing share price

$5.35
Osiris Therapeutics's latest market capitalization is $179 M.

Osiris Therapeutics Market Value History

Osiris Therapeutics News

Osiris Therapeutics Company Life